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PATENT PROSECUTION IN PROTEOMICS
Keala Chan and Dennis Fernandez

I.

INTRODUCTION: AN INTELLECTUAL PROPERTY OVERVIEW

Some find the concept of intellectual property hard to grasp,
often because it's hard to determine the monetary worth of ideas.
One simple example of the value of intellectual property is the
common occurrence of expensive and high-stakes infringement
lawsuits. One of the costliest examples is the decades-long case of
Eastman Kodak vs. Polaroid,which resulted in the destruction of
Kodak's instant photography business, as well as more than three
billion dollars in infringement damages, compensation and legal fees,
and research and manufacturing costs.' Even lawsuits that result in
settlements, such as that filed by the University of California against
Genentech for the company's manufacture and sale of the growth
hormone product Protropin®, can be severe ($200 million in the case
of UC vs. Genentech) punishments for the defendants. 2 That is not to
mention the hundreds of thousands of dollars lost by both sides on
legal and courtroom fees and on time spent by employees and
management embroiled in the suit.
Although successful suits filed by small companies can result in
large settlements or infringement damages from industry juggernauts,
companies without the proverbial "deep pockets" typically do not
have the resource to spend on lengthy, costly litigation. The price of
resolving patent disputes can sometimes cripple a business, compared
with the modest cost of building an effective IP portfolio. Thus,
successful companies stand to benefit more from a strong IP portfolio
to accompany equally strong and innovative research and
development. Besides, with sound and successful innovation, a

1. Kevin G. Rivette & David Kline, A Hidden Weapon for High-Tech Battles, UPSIDE,
Jan. 2000, at 165-74.
2. Timothy Kudo, Regents Drop Case Against Genentech, Agree to Settle, UCLA DAILY
BRUIN ONLINE, Nov. 22, 1999, availableat
http://www.dailybruin.ucla.edu/db/issues/99/l11.22/news.settlement.html.
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company can avoid being mired in litigation over a technology that it
has long since improved upon.
From a different angle, those still questioning the value of
intellectual property can look at the value derived from successful
licensing of IP. The well-known Cohen-Boyer recombinant DNA
patents, often credited as key catalysts of today's biotech industry,
were reported to have earned $37.3 million in licensing royalties in
1997 alone. 3
While U.S. legislation, such as the Bayh-Dole Act, allowed for
transfer of ownership of many government-funded inventions from
the U.S. government to the universities, 4 resulting in successful
licensing of almost half of university-born inventions, 5 the fact is that
an estimated 3% of all patents are actually licensed. 6 Thus an
effective IP prosecution strategy should take note of the competing
demands for licensing revenue and defense from litigious
competitors. On the one hand, well-written patents are needed to
defend the core technologies a company builds upon, and on the other
hand an aggressive patenting strategy is needed to map the course a
company sees itself undertaking. The latter can result in licensing
deals, or serve as a useful method for sidestepping unwanted
litigation, by keeping far ahead of the competition.
This Article presents a brief overview of intellectual property
rights and the various areas in proteomics to which IP rights may be
applicable. The perfection of an IP portfolio is of interest to startups
and their investors, whereas licensing agreements are of interest to
manufacturers and customers.
Technology transfer, including
licensing and business agreements, is not covered in this Article.
Instead, issues and complications related to national and overseas
patent prosecution in this relatively new field will be discussed.

3.

Fact File: Office of Technology Licensing, MEDICAL STAFF UPDATE (Stanford

Hospital and Clinics, Stanford, CA), Dec. 1998, available at
med.stanford.edu/shs/update/archives/dec] 998/fact.html.
4. Consumer
Project
on
Technology,
The
Bayh-Dole
http://cptech.org/ip/health/bd (last visited Mar. 4, 2003).

http://wwwAct,

at

5.
Kenneth D. Campbell, TLO Says Government Research Pays Off Through $3 Billion
in
Taxes,
MIT
TECH
TALK,
Apr.
15,
1998,
available
at
http://web.mit.edu/newsoffice/tt/1998/aprl5/patents.html. See generally The Bayh-Dole Act: A
Guide to the Law and Implementing Regulations, COUNCIL ON GOVERNMENTAL REGULATIONS

(Council on Government Regulations, Washington, D.C.), Oct. 1999, available at
http://www.cogr.edu/Bayh-Dole.pdf (last visited Mar. 4, 2003 ) (discussing the Bayh-Dole Act's
impact on governmental patent licensing).
6.

Interview with Emmett J Murtha, LICENSING ECONOMICS REV., Oct. 2001, at 9-10.
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A.

Patents

United States patents offer protection for any process, machine,
manufacture, or composition of matter, or any improvement thereof,
that are novel, useful, and non-obvious.] The Agreement in TradeRelated Aspects of Intellectual Property Rights (TRIPS Agreements)
in 1994, a multilateral concord proposed by the council administering
the WTO's intellectual property agreement, 8 defines patentable matter
as any invention that involves an innovative step and has a potential
9
industrial application.
In theory, the purpose of intellectual property is to foster
intellectual and economic growth. Patents spur innovation through
the disclosure and teaching of the details of an invention to the public,
and in exchange, the inventor or owner is rewarded the legal rights of
ownership. The legal rights give the owner exclusive rights to
capitalize on the invention, by excluding others from making or using
the invention, importing the invention into the U.S., or offering the
invention for sale; these ownership rights are granted for a period of
17-20 years, depending on the date of filing of the patent.10
Patents are obtained through a lengthy process that can
sometimes turn out to be quite costly. In high-tech fields such as
proteomics, the time between filing a patent and a first response from
the U.S. patent office is typically a year and a half. This is due in part
to the large volume of patent applications in these fields, and to the
lack of expertise in the patent examiner corps. In Europe, Japan, and
the Pacific, the "first to file" system applies." On the other hand, in
the U.S., the "first-to-invent" system applies, but patent applications
must be filed within one year of the first offer for sale of the product
or the patent filing will be void. Thus, it is important to keep an
accurate record of dates of invention, as well as offers for sale or
other public disclosures.

7.

35 U.S.C. §§ 101-103 (2000).

8.

Overview:

the

TRIPS

Agreement,

WORLD

TRADE

ORGANIZATION,

at

http://www.wto/org/english/tratope/trips-e/intel2_e.htm (last visited Mar. 4, 2003).
9. Kevin W. McCabe, The January 1999 Review ofArticle 27 of the TRIPS Agreement:
Diverging Views of Developed and Developing Countries Toward the Patentability of
Biotechnology, 6 J. INTELL. PROP. L. 41, 50 (1998).

10. See DONALD CHISUM, ET AL, PRINCIPLES OF PATENT LAW: CASES AND MATERIALS
(Foundation Press, 2001).
11.
See id
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B.

Copyrights

Copyrights protect the original expression of an idea.' 2 By
offering protection, copyright encourages the expression of original,
artistic ideas into a tangible medium. Legal protection is effected
instantly, when the original copyrightable subject matter is fixed into
a tangible medium, e.g. on paper or in a digital storage form.
Copyrights are free and do not require months of paperwork as do
patents, and they are valid for the author's lifetime plus 70 years. A
longer period of validity (75-100 years) applies if the work was
created for hire, which is generally the case in a business such as the
biotech industry. 13
C. Trade Secrets
Trade secrets are any technical or business information that give
a company a competitive advantage. 14 There is no formal filing
procedure to register trade secrets. The secret need not be completely
novel or exclusive; it simply must have a derived or potential
economic value from being unknown.
Additionally, reasonable
efforts must be made to keep the information secret, e.g. through the
inexpensive use of Non-Disclosure Agreements (NDA).
Legal
protection under trade secret no longer applies when the information
is publicly disseminated.
D.

Trademarks

Trademarks refer to the distinctive signature mark that can be
used to protect the company, product, service, name, or symbol. The
trademark must not be descriptive or generic. Legal protection is not
offered to the technology, but rather to the company good will and5
quality associated with the use of the recognized name or symbol.'
Trademarks provide exclusive rights within a region or nation as long
as they are used commercially, and they may be renewed indefinitely.
Compared to patents, they are obtained within a moderate time period
(usually under two years) and typically at a cost under $5,000 per
12.

See SHELDON HALPERN, COPYRIGHT LAW: PROTECTION OF ORIGINAL EXPRESSION

(Carolina Academic Press, 2002).
13.

Id.

14. See HOWARD C. ANAWALT & ELIZABETH ENAYATI POWERS, IP STRATEGYCOMPLETE INTELLECTUAL PROPERTY PLANNING, ACCESS, AND PROTECTION, (West Group
2001) § 1.01, at 1-3.
15.
See generally HOWARD C. ANAWALT & ELIZABETH ENAYATI POWERS, IP
STRATEGY-COMPLETE INTELLECTUAL PROPERTY PLANNING, ACCESS, AND PROTECTION,
(West Group 2001).
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registered mark.
E. IP Strategy
The IP rights are protected under various federal and state laws.
Without protection, intellectual property falls into the public domain
and may be used by any party without license. A sound management
strategy would be to systematically build a portfolio consisting of
different IP rights, with the aim of protecting the various aspects of
the company's technology and commercial interests.
IP rights protect the commercial interests of a company at the
various stages of design, manufacturing, and product operation. At
the design and development stage, copyrights and trade secrets can be
immediately enforced. Novel apparatus and methods can then be
patented, a process that takes about three years and requires the
investment of some funds. Once a product or service is developed,
issued patents and trademarks protect the technology and associated
names and symbols.
While copyright and trade secret protection are obtained easily,
patents, trademarks, and maskworks require applicant action and
response within critical filing deadlines. Generally, the first to patent
will have the best chance of winning the broadest patents.
II. PROTEOMICS
The term proteome is often used to describe the total set of
proteins expressed during the lifetime of a cell. 16 Proteomics, a term
coined to convey the largely informational nature of the problem of
categorizing the proteome, is sometimes associated with structural
genomics, which is the study of how protein structure and function
relate to genes. In practice, proteomics involves everything from
structure determination, at the lowest level, to functional analysis, and
finally to cell modeling.
At the most fundamental level, scientists attempt to determine
the composition and structure of individual proteins. This difficult
task necessitates discovery of primary structure (the chemical bonds
and sequence of amino acids comprising the protein), the secondary
structure (existence of typical forms such as a-helixes, P-sheets),
tertiary structure (the way in which secondary structures fold in 3dimensions, see Figure 1), and quarternary structure (organization of

16. See P.C. TURNER ET AL., INSTANT NOTES IN MOLECULAR BIOLOGY (Springer-Verlag
New York 2d ed.) (2000).
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polypeptide chains) of the protein. 17

-sheet
a-helix

Figure 1: Baculovirus P351

With knowledge of protein structure, the function of a particular
protein, whether for transport, storage, communication, etc., can often
be deduced. Still, knowledge of protein structure is not always
enough to describe completely a protein's role in the cell. A
comprehensive functional analysis must ultimately be performed by
experimenting with gene mutations and environmental perturbations.
With such a totality of information, predictive cell models may
eventually be developed.
Protein structure determination, by far the most basic and
essential task of proteomics, is estimated to cost upwards of $100,000
per protein structure determined, not to mention a discovery time that
can stretch from months to years."8 For this reason the National
Institutes of General Medical Science (NIGMS), a division associated
with the National Institutes of Health (NIH) began a major funding
effort in 2000 to build the tools and machinery needed to enhance
research in this field. 19 The goal is to reduce the cost of determining
protein structure to $10,000 to $20,000 per protein by grouping them
into structural families and solving structures of representative
proteins from each family, thereby creating a skeleton model of a

17. Id.
18. See Press Release, Rutgers, the State University of New Jersey, Rutgers-Led
Consortium Awarded $6.5 Million by NIH for Genomic Research (Nov. 12, 2002) available at
http://www.eurekalert.org/pub releases/2002- 1/rtsu-rcal 11202.php (last visited Mar. 4, 2003).
19. Alisa Machalek. NIGMS Structural Genomics Awards Scale Up Protein Structure
Studies, NIH News Release. Sept. 2000.
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complete protein inventory. 20 By 2005, each research project is
expected to solve 100 to 200 protein structures annually, with a total
of about 10,000 structures solved over 10 years. 21 The fund is
managed by the Protein Structure Initiative (PSI), which was
anticipated to distribute a total of $150 million over the course of
2000-2005.2" While European spending on proteomics research lags
behind the U.S., several publicly funded research programs have
recently been launched in accordance with the Sixth Framework
Programme (FP6) of the European Commission, which has devoted
an overall budget of approximately $18 billion to the advancement of
the European research community, of which proteomics research is a
23
recent addition.
As with many research trends, determination of protein structure
is sometimes thought of as a panacea for everything from the
environment to national security. In fact, proteomics and structural
genomics research have already yielded valuable results in drug
design. One example is the development of inhibitors for HIV
reverse transcriptase (RT), an enzyme vital for the replication of the
virus. 24 With knowledge of crystal structures, scientists were able to
identify optimal sites for disruption of RT function, resulting in
successful non-nucleoside RT-inhibitors (NNRTIs).25
While it is clear that proteomics has valuable applications to
human health, few large drug companies perform protein structure
research or structure-based drug development because of high costs,
relying instead on available structural information and trial-and-error
26
to discover the compounds that activate or disable target proteins.
The huge cost of structure discovery is due in part to the lack of highthroughput tools and machines needed to accelerate present molecular
structure discovery methods. X-ray crystallography, the most widely
used method, requires gene cloning, protein expression, and protein
purification and crystallization, all processes that, until very recently,

20.

Id.

21.

Id.

22.

Id.

23.
Commission of the European Communities, Decision of the European Parliament
and of the Council, Nov. 2001.
24.
Yang Liu et al., Structural Genomics: A New Erafor PharmaceuticalResearch, 3
GENOME BIOLOGY 4004.1- 4004.3 (2002).
25.

Id.

26.
See Ken Garber, The Next Wave of Genomics Business, TECH. REV. 46, 48 (July-Aug.
2002) available at http://www.imakenews.com/techreview/earticleOO0005757.cfm (last visited
Aug. 28, 2000).
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still involved painstaking laboratory hours.27 Thus, until the millions
of dollars in government funding poured into national research
centers results in the development of high-throughput devices and
infrastructure for protein structure research, proteomics will remain
mainly in the research stage, with most structure determination
performed by funded research centers.
Currently there are numerous protein structure databases, with
emphases on different aspects such as three-dimensional structure or
protein families. The Protein Data Bank (PDB), a comprehensive
depository of three dimensional structural data, 28 has around 19,000
protein structures archived.
Although not even close to a
comprehensive knowledge about the set of human proteins, of which
the human genome probably encodes about 300,000, the various
databases and worldwide funding efforts recently implemented
29
suggest that real proteomics applications are just around the comer.
A.

ProtectableApplications in Proteomics
1. Tools

The tools, methods, and infrastructure implemented to advance
the state of protein structure research are excellent candidates for
lucrative patents because well-designed tools can become essential to
the research process of the entire industry. The potential for licensing
these "tollbooth" technologies is immense, as in the case of the
Cohen-Boyer recombinant DNA patents, which, before they expired
in 1997, could be said to be infringed anytime anyone cloned DNA.30
a. Software
Software for the collection, visualization, and prediction of
protein structure data are all becoming important tools in the
proteomics research process. This combination of informational
science with cell biology is often referred to as bioinformatics, the
study of high-throughput, automated information search and retrieval
methods for the massive amounts of DNA, cell, and protein data
27.
Raymond C. Stevens & Ian A. Wilson, Industrializing Structural Biology, 293
SCIENCE 519, 520 (2001).

28.

See John Westbrook et al., The Protein Data Bank and Structural Genomics, 31

NUCLEIC ACIDS RESEARCH 489-491 (2003).

29. William J. Cromie, Scientists Ponder Sequence of Genes, HARV. GAZETTE (Apr. 5,
2001), at http://www.news.harvard.edu/gazette/2001/04.05/07-genes.html (last visited April 8,
2003).
30.
MEDICAL STAFF UPDATE, supra note 3.
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accumulated each year by the scientific community. In proteomics,
several public protein structure databases contain thousands of protein
structures each, with more information being added each month. Data
collection is also a vital element of proteomics, since efficient and
adaptable methods are necessary to gather the continuous flow of data
from various research facilities. Currently, to reduce the burden of
data processing taken on by research centers, databases such as the
PDB have created software for data annotation, translation, and input
to automate the data deposit process. 3'
The databases and
accompanying automated data collection and search methods are all
protectable IP.
Software for protein structure prediction often involves matching
a partial structure to known family representatives stored in a
database. This type of prediction relies on sophisticated search
algorithms, which can be patented in combination with the database
that stores protein information. Types of prediction methods can
range from sequence homology to methods as intricate as 3-D
structure-based alignment. 32 As more protein structures are solved, 3D structure visualization becomes important not only for some
prediction methods, but also as an educational tool. Software patents
for structure prediction or 3-D visualization tools are similar to
computer software patents.
b.

Devices and Methods

A number of steps are involved in determining protein structure
and in proteomics in general. Protecting the devices and methods that
assist the proteomics research process is a standard practice.
In proteomics research, proteins must be isolated in a step known
as separation. There can be ten to twenty thousand different proteins
expressed in a single cell, so refined identification and separation
techniques are essential.
Mass spectroscopy, peptide mass
fingerprinting, and liquid chromatography are commonly used
techniques, with capillary electrophoresis emerging as a potentially
powerful new method for protein separation.3 3 There are numerous
devices on the research device market to automate separation. For
example, the several varieties of capillary electrophoresis, all of

31.

Westbrook, supra note 23, at 489-91.

32.

See generally MINORU KANEHISA, POST-GENOME INFORMATICS (Oxford University

Press 2000).
33.

See Cort Wrotnowski, Capillary Electrophoresisfor Proteomics Projects, GENETIC

ENGINEERING NEWS,

Jan. 1, 2003.

466 COMPUTER & HIGH TECHNOLOGY LAW JOURNAL [Vol. 19
which have their own advantages, also have their own machines and
digitized systems.3 4 One trend is towards hybrid instruments, systems
that use combinations of techniques (such as capillary electrophoresis
and liquid chromatography) for wider scope of functions.35
Laboratory tools such as these, each of which improve upon a
previous machine or method, are typical candidates for device and
method patents. 36
The trend towards lab-on-chip devices that
combine electronics with the cell biology fundamental to proteomics
makes for more complicated patents; indeed, few have the
interdisciplinary training needed to write or examine patents in this
relatively new, cross-technical discipline.
Cloning and expression of proteins is another bottleneck in
proteomics research. Currently there is a need for high-throughput:
high-yield methods for protein expression. Moreover, the production
of property folded proteins is another challenge to systematic
magnification of purified proteins.
Finally, the primary method for protein structure research has
been x-ray crystallography, with nuclear magnetic resonance (NMR)
a close second.37 These processes, too, have a host of systems and
methods to facilitate laboratory research. One bottleneck in x-ray
crystallization is the production of crystallized proteins, which some
companies have attempted to automate with robots. 38 Refinements in
systems and methods for protein expression and structure
determination will be reflected in the devices that are invented to
automate the improvements.
2.

Diagnostics

Using protein markers to detect disease is one important
application of proteomics to human health. Devices that check for
elevated levels of certain proteins can serve as ultra-sensitive
diagnostic tools for cancer and other hard to predict diseases.39 For
example, UC Berkeley researchers have been involved in the design
of a micro-cantilever that detects the presence of prostate specific
antigen (PSA), a prostate cancer marker found in the blood, at levels
34.

Id.

35.

Id.

36.

Id.

37.
See Enrique Abola et al.,
STRUCTURAL BIOLOGY, Nov. 1,2000.

38.

Automation of X-Ray

Crystallography, NATURE

Id.

39.
See Guanghua Wu et al., Bioassay of Prostate-Specific Antigen (PSA)
Microcantilevers, 19 NATURE BIOTECHNOLOGY 856-860 (2001).

Using
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twenty times lower than the clinical threshold. 40 The micro-cantilever
is an inventive device for the detection of a protein that is known to
be associated with the disease. A more traditional device in the
industry that will likely be used more frequently for protein marker
detection is the protein array, a variation on the now standard DNA
array. Use of protein markers can even extend from diagnostics and
into methods for devising optimal treatment or for measuring
progression or response to treatment.4 ' Speedy detection of protein
markers can also be a means to accelerate clinical trials.
While a protein marker itself would not be patentable material
unless isolated from nature, a novel device or method for detection of
proteins, especially if such a detection has great therapeutic worth,
would be valuable indeed. In some cases, however, it is necessary to
claim both the detection method and the structure of the protein
marker itself, in order to ensure successful prosecution of a protein
marker patent.
3. Structure-Based Drug Design
Structure-based drug design is still in its infancy in the
pharmaceutical industry, making the practice a breeding ground for
emerging industry standards. While combinatorial chemistry has
been the method of choice in lead identification, understanding of
protein structures lends itself nicely to screening of the molecules
yielded from combinatorial chemistry.42 More commonly, protein
structure data is used to optimize drug leads; for example, to modify
molecules to achieve more potency.4 3 In these cases, innovations in
software and the accompanying databases of protein structure and
ligand docking information will be the main drivers of the
combination of structure-based and combinatorial chemistry drug
design.
Of course, it is also customary to patent the drugs themselves.
Generally, molecular structures and functions involved in the
therapeutic process should be described in the specification. Further,
unless the drug can be shown to have the alleged effect in humans, or

40.

Id.

41.

Proteome Sciences, The Science of Proteomics at

http://www.proteome.co.uk/proteomics/, at 6 (last visited April 8, 2003).
42. See Celia M. Henry, Structure-Based Drug Design, CHEMICAL & ENGINEERING
NEWS, June 4, 2001, 69-74, availableat

http://pubs.acs.org/cen/coverstory/7923/7923drugdesign.html (last visited Apr. 1, 2003).
43. Id.
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the desired species, the drug in question often will not pass either the
utility or the enablement requirement needed to prove patentability.
Although it is of strategic importance to patent potential drugs that
seem likely to pass human clinical trials, it is advisable to detail
specific physical and chemical functions in order to avoid forced
amendments that might limit the scope of the patent.
Another issue involved in the drug patent process is the fact that
obtaining FDA approval for a drug often takes substantially longer
than patent prosecution, effectively reducing the term of the patent
once issued. One patent term extension is available, however, under
the U.S. code, for products that were subject to regulatory review.44
B.

Challenges to PatentProsecution in Proteomics

As already touched upon, there exist some challenges that are
specific to the proteomics patent process. For example, while it is
important to claim the function or "mechanism" of particular
molecules in order to provide enabling description of certain drugs,
general claims based purely on the mechanism may prove to be too
generic as well. Very general mechanism claims to support Pfizer's
Viagra drug, for instance, "a method of treating erectile dysfunction
in a male human, comprising orally administering to a male human in
need of such treatment an effective amount of a selective cGMP
PDEv inhibitor, or a pharmaceutically acceptable salt thereof, of a
pharmaceutical composition containing either entity," will soon be
tested in upcoming court battles.45 Because the claim is so general,
describing only the type of inhibitor and its function, the patent has
the potential to include selective cGMP PDEv inhibitor compounds
that achieve the desired function, which have yet to be discovered.4 6
Some feel that mechanism claims will be contested and found invalid
during litigation because, for instance, they do not meet the
requirement that genus claims disclose a representative number of
species in order to show possession of the genus (in this case a
method for treating erectile dysfunction using a specific inhibitor).47
Another type of proteomics-related claim construction in
question is the "reach through" claim, "which attempts to claim
compounds which may be identified by a screening procedure,

44.

35 U.S.C. § 156 (2000).

45.

See generally Leslie M. Levine & Paula Campbell Evans, Legal Affairs: New

Challenge to Mechanism Claims in Patents, GENETIC ENGINEERING NEWS, Jan. 1, 2003.
46.

Id.

47.

Id.
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' 8
without having to specifically identify any specific compound.A
For
example, a claim listing "an isolated receptor agonist wherein said
receptor agonist is identified by the method of Claim X" that does not
contain support in the specifications, in particular detailing the
structure or function of the claimed receptor agonist, is likely to be
rejected. 49 In the European Patent Office (EPO), no search will be
performed for compounds only defined by the method for their
identification.50 In the US Patent Office, on the other hand, the
rejection might be overcome if it can be shown that one of ordinary
skill in the art would be expected to know that a particularly disclosed
receptor agonist is representative of a family of molecules that can be
identified by the claimed method.5' Of course, the rejection can also
be overcome by limiting the scope of the claim to specifically
disclosed receptor agonists, if such agonists were in fact disclosed.
The EPO also has specific laws pertaining to biotechnology
patents, described in the EU Biotechnology Directive of July 1998,
and the European Patent Convention (EPC) of 1999. For instance,
Article 53(a) of the EPC states that "European patents shall not be
granted in respect of... inventions the publication or exploitation of
which would be contrary to 'ordre public' or morality, ' '52 and Rule
23d (d) excludes "processes for modifying the genetic identity of
animals which are likely to cause them suffering without any
substantial medical benefit to man or animal, and also animals
resulting from such processes., 53 Thus, patents that cover genetically
modified animals, for example, that do not specify or imply medical
benefits can be rejected by the EPO or challenged in an opposition, a
procedure in which any person may oppose a granted European patent
within nine months from publication.
Finally, the notable rule pertaining specifically to biotechnology
patents in both the US and Europe is that of utility. Under amended

48. Carmella L. Stevens, Reach Through PatentClaims in Europe,BAKER BOTTS IP REP.
(Baker Botts LLP, New York, NY), May 2002, at
http://www.bakerbotts.com/news/print.asp?pubid= 10757302002 (May 1, 2002).
49. See TRILATERAL PROJECT B3B, Report on Comparative Study on Biotechnology
Patent Practices; Theme: Comparative Study on "'Reach-Through Claims," Nov. 2001, at

http://www.uspto.gov/web/tws/B3b-reachthrough.pdf.
50. Id.
51. Id.
52. European Patent Convention, Oct. 5, 1973, art. 53(a), at http://www.European-patentoffice.org/epc/pdf e.htm (most recently updated July 1, 2002).
53. Implementing Regulations to the Convention on the Grant of European Patents, Oct.
5, 1973, rule 23d (d), http://www.European-patent-office.org/epc/pdf e.htm (last modified Dec.
13, 2001).
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guidelines, patentable subject matter is that which has specific,
substantial, and credible utility. The addition of the substantiality
requirement means that patent claims that require considerable
research by a person of ordinary skill in the art in order to determine
the function of a molecule are likely to be rejected. The motivation
for the requirement is to reduce claims that expand beyond the scope
of the invention's the function and utility described in the
specifications. In its most simplified interpretation, the utility rule
demands that each claim pertain to products that have a clear use and
benefit to human society.

III. CONCLUSION
The challenges to proteomics patents are still evolving. Because
of their direct application to biological life on earth, proteomics and
genomics patents are subject to intense scrutiny by the various patent
offices. As the technology develops, however, one impedance to the
biotech patent process, namely, the need for more cross-technically
educated patent examiners and counsel, will eventually become less
of a burden. Knowledge of the challenges to the proteomics patent
process will lead to more skillful prosecution and more rapid
innovation overall.

